# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN
- Date: 2026-01-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results of colonoscopy, MR enterography, and tuberculosis tests. **S**

## History of present illness

Ms. Boulanger returns nine days after presenting with four months of right lower abdominal cramping, loose stools up to six times a day and at night, evening fevers, and loss of 6 kg. The ileocolonoscopy five days ago showed deep longitudinal ulcers over the last 15 cm of the terminal ileum and patchy ulcers in the ascending and transverse colon with normal mucosa between and a spared rectum (SES-CD 14). The biopsies show chronic active ileitis and colitis with crypt distortion and a few small non-caseating granulomas; the acid-fast stain and TB PCR are negative and the mycobacterial culture is pending. MR enterography two days ago shows 18 cm of inflamed terminal ileum without stricture, fistula, abscess, or necrotic nodes. The interferon-gamma release assay is negative and the chest X-ray normal. Stool tests for Clostridioides difficile, bacterial pathogens, and parasites are negative, and celiac serology is negative. The pregnancy test is negative. She has five or six loose stools a day with cramping and fatigue (Harvey-Bradshaw Index 11). She met Dr. Nwankwo-Delacroix this morning and chose a treatment with him. She has a concert of her choral works in late March and asked whether she could still perform. **S**

| Element | Detail |
|---|---|
| Endoscopy | Ileocolonic ulceration, SES-CD 14; rectum spared |
| Histology | Chronic active ileocolitis with small non-caseating granulomas; AFB and TB PCR negative; culture pending |
| Imaging | 18 cm of inflamed terminal ileum; no stricture, fistula, or abscess |
| Infection screen | IGRA negative; chest X-ray normal; HBsAg and anti-HBc negative, anti-HBs below 10; HCV and HIV negative; measles and varicella IgG positive |
| Activity | Harvey-Bradshaw Index 11 (moderate) |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue and evening fevers to 37.6 °C; weight steady this week |
| Gastrointestinal | Positive | Five or six loose stools a day, one at night; right lower quadrant cramps; no blood |
| Eyes | Negative | No red or painful eyes |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No tender red nodules on the shins |
| Psychiatric | Positive | Low and anxious about the concert; PHQ-9 8, GAD-7 9 |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs **S**
- Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect **S**
- Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily **S**
- Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone **S**

## Allergies

- No known allergy **S**

## Objective

BP 102/64 mmHg; pulse 92 bpm; respirations 16/min; temperature 37.4 °C; oxygen saturation 99% on room air; weight 44.8 kg; BMI 17.5 kg/m². All vital signs are synthetic.

PHQ-9: 8; GAD-7: 9; ALT: 18 U/L; AST: 20 U/L; Total bilirubin: 0.4 mg/dL; Lumbar spine Z-score (DXA): -1.4; Femoral neck Z-score (DXA): -1.1. All results are synthetic.

## Change since baseline

- ALT: 16 U/L at baseline, 18 U/L at this visit **S**
- AST: 19 U/L at baseline, 20 U/L at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20, before immunosuppression **S**
- Recombinant zoster vaccine, dose 1 of 2, before immunosuppression **S**
- Hepatitis B vaccine, adult booster dose (infant series, anti-HBs below 10 mIU/mL) **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin and tired; BMI 17.5 |
| Mouth | Two small aphthous ulcers inside the lower lip |
| Abdomen | Tender in the right lower quadrant with fullness but no discrete mass; no guarding |
| Perianal | No fistula, abscess, or skin tags |
| Skin | No erythema nodosum |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Crohn disease of the terminal ileum and colon, Montreal A2 L3 B1, moderate to severe** (K50.80). The endoscopic pattern (long ileal ulcers, skip lesions, spared rectum), small non-caseating granulomas, and imaging fit Crohn disease. Intestinal tuberculosis, the main alternative, is very unlikely: negative interferon-gamma release assay, normal chest X-ray, no caseating or confluent granulomas, and negative acid-fast stain and TB PCR; the culture will be checked at six weeks. Her features predict a disabling course (young age, extensive and deep ulcers, weight loss), so an advanced therapy should start now rather than after other drugs fail. She was told the diagnosis directly, with what it means for her life and work. **S**
   - Risankizumab 600 mg intravenously at weeks 0, 4, and 8, the first infusion in five days, then 360 mg under the skin every 8 weeks; chosen by her with Dr. Nwankwo-Delacroix.
   - Prednisone 40 mg daily from today, reduced by 5 mg each week to stop in eight weeks, as a bridge.
   - Liver enzymes and bilirubin today and through at least week 12.
   - She can plan to perform in March; a plan for bathroom access at the venue.
2. **Iron deficiency anemia** (D50.0). Hemoglobin 10.6 and ferritin 9 with active inflammation: oral iron is poorly absorbed and can worsen symptoms. **S**
   - Ferric derisomaltose 1000 mg intravenously with the first risankizumab infusion; phosphate checked at the next visit.
3. **Moderate protein-calorie malnutrition** (E44.0). BMI 17.5 after a 12 percent weight loss; albumin 3.3. **S**
   - Dietitian seen today: small frequent meals and two oral nutritional supplements a day.
   - Weight at every visit.
4. **Vitamin D deficiency, with a course of prednisone ahead** (E55.9). Vitamin D 18 ng/mL; DXA today within the expected range for age (Z-scores -1.4 and -1.1). **S**
   - Vitamin D3 2000 units daily; calcium carbonate 1250 mg daily while on prednisone.
   - No repeat DXA unless steroids are needed again.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Ileocolonoscopy with biopsies | At diagnosis | Up to date | Five days ago: SES-CD 14; chronic active ileocolitis with small non-caseating granulomas |
| Imaging | Cross-sectional imaging of the small bowel (MR enterography) | At diagnosis, for extent and complications | Up to date | Two days ago: 18 cm of inflamed terminal ileum; no stricture, fistula, or abscess |
| Laboratory | Exclusion of intestinal tuberculosis: biopsy acid-fast stain, TB PCR, and mycobacterial culture | At diagnosis, before immunosuppression | Up to date | Acid-fast stain and TB PCR negative; culture pending, to be reviewed at six weeks |
| Laboratory | Latent tuberculosis screen (interferon-gamma release assay) and chest X-ray | Before steroids or a biologic | Up to date | IGRA negative; chest X-ray normal |
| Laboratory | Hepatitis B, hepatitis C, and HIV screening | Before immunosuppression | Up to date | HBsAg and anti-HBc negative; anti-HBs below 10 mIU/mL after an infant series; HCV antibody and HIV negative |
| Laboratory | Stool tests for Clostridioides difficile and enteric pathogens; celiac serology | At diagnosis | Up to date | All negative |
| Laboratory | Liver enzymes and bilirubin before risankizumab | At baseline | Completed today | ALT 18, AST 20, bilirubin 0.4 |
| Medication safety | Vaccines before immunosuppression | Before starting, when possible | Completed today | PCV20, recombinant zoster dose 1, and a hepatitis B booster today; immune to measles and varicella, so no live vaccine is needed and treatment need not wait |
| Laboratory | Hepatitis B antibody after the booster | One to two months after the dose | Due | At the next visit |
| Imaging | Bone density (DXA) | At diagnosis with risk factors (low weight, vitamin D deficiency, corticosteroids) | Completed today | Lumbar spine Z-score -1.4, femoral neck -1.1: within the expected range for age |
| Survey | Depression and anxiety screen (PHQ-9 and GAD-7) | At diagnosis and at least yearly | Completed today | PHQ-9 8 and GAD-7 9, mild; offered the IBD psychology service |
| Referral | Gastroenterology (inflammatory bowel disease) | At diagnosis | Completed today | Seen this morning; recommendations in the consultation note |
| Self-management | Dietitian and nutrition plan | At diagnosis with weight loss | Completed today | Seen today; supplements started |
| Self-management | Contraception and pregnancy planning | At diagnosis for women of reproductive age | Completed today | Not sexually active; pregnancy test negative; counseled to avoid pregnancy while the disease is active and to plan any pregnancy in remission |
| Self-management | Smoking status | Every visit | Completed today | Never smoker |

## Goal progress

- Reach a diagnosis, with tuberculosis excluded, within two weeks. Outcome by 2026-01-28: Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending. **S**
- Steroid-free clinical remission by week 12 to 16 of treatment. In progress; target 2026-04-27. **S**
- Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months. In progress; target 2026-10-05. **S**
- Regain weight to a BMI of 19 or more and correct iron and vitamin D. In progress; target 2026-08-03. **S**
- Perform her March concert and keep composing through treatment. In progress; target 2026-04-27. **S**

## Medication changes

- Started: Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect **S**
- Started: Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily **S**
- Started: Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone **S**

## Guideline basis

- ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025), American College of Gastroenterology
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021 (2021), American Gastroenterological Association
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024), European Crohn's and Colitis Organisation
- ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026), European Crohn's and Colitis Organisation
- ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025), American College of Gastroenterology
- SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026), U.S. National Library of Medicine, DailyMed

## Follow-up

- First risankizumab infusion and intravenous iron in five days. Review at the second infusion, in four weeks. **S**
- Next scheduled visit 2026-03-02: review at week 4 of risankizumab, on the day of the second induction infusion. **S**
